From development candidates to clinical PoC is the decree of Anbogen Therapeutics (ABT). Anbogen aimed at developing precision oncology medicines by targeting driver genes in cancers with unmet therapeutic needs. Founders are experienced scientists with successful R&D track records from Eli Lily, Merck & Co., and National Health Research Institutes in Taiwan. We are seeking for potential partnership and collaboration. Our ABT-101 targets to treat non-small-cell lung cancer (NSCLC) patients harboring HER2 exon 20 insertion (HER2e20i). ABT-101 holds the best-in-its-class drug premises owing to early safety data in human and a series of head-to-head studies with competitor compounds. Taiwan Food and Drug Administration (TFDA) has approved a Phase 1b/2 clinical trial for ABT-101 to treat NSCLC with HER2e20i. This trial is the start of a global development program. ABT-201, targeting KRAS, is superior to sotorasib with respect to its enzyme inhibitory capability toward KRASG12C. In accordance to results from a completed Phase 1 trial, ABT-301, a histone deacetylase inhibitor (HDACi), has the most assuring safety/PK profile among its class. Phase 2 trials will be focusing on assessing the ability of ABT-301 to enhance current therapeutics in cancers with biomarkers reflecting pathologic aberrations amenable to ABT-301 intervention.